201 related articles for article (PubMed ID: 36150999)
1. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
[TBL] [Abstract][Full Text] [Related]
2. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
[TBL] [Abstract][Full Text] [Related]
3. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
Phillips A; Clark T
Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
[TBL] [Abstract][Full Text] [Related]
4. Understanding estimands.
Gogtay NJ; Ranganathan P; Aggarwal R
Perspect Clin Res; 2021; 12(2):106-112. PubMed ID: 34012908
[TBL] [Abstract][Full Text] [Related]
5. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
6. A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis.
Mehrotra DV
Clin Trials; 2019 Aug; 16(4):339-344. PubMed ID: 30977390
[TBL] [Abstract][Full Text] [Related]
7. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
8. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
9. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
[TBL] [Abstract][Full Text] [Related]
10. Disentangling estimands and the intention-to-treat principle.
Leuchs AK; Brandt A; Zinserling J; Benda N
Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
[TBL] [Abstract][Full Text] [Related]
11. Estimands in hematologic oncology trials.
Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
[TBL] [Abstract][Full Text] [Related]
12. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
13. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
[TBL] [Abstract][Full Text] [Related]
14. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
15. Application of the Estimand Framework to Anesthesia Trials.
De Silva AP; Leslie K; Braat S; Grobler AC
Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
[TBL] [Abstract][Full Text] [Related]
16. Estimands and Complex Innovative Designs.
Collignon O; Schiel A; Burman CF; Rufibach K; Posch M; Bretz F
Clin Pharmacol Ther; 2022 Dec; 112(6):1183-1190. PubMed ID: 35253205
[TBL] [Abstract][Full Text] [Related]
17. What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD.
Keene ON; Ruberg S; Schacht A; Akacha M; Lawrance R; Berglind A; Wright D
Pharm Stat; 2020 Jul; 19(4):370-387. PubMed ID: 31919979
[TBL] [Abstract][Full Text] [Related]
18. A constructive critique of the
Scharfstein DO
Clin Trials; 2019 Aug; 16(4):375-380. PubMed ID: 31184495
[TBL] [Abstract][Full Text] [Related]
19. Principles and recommendations for incorporating estimands into clinical study protocol templates.
Lynggaard H; Bell J; Lösch C; Besseghir A; Rantell K; Schoder V; Lanius V
Trials; 2022 Aug; 23(1):685. PubMed ID: 35986349
[TBL] [Abstract][Full Text] [Related]
20. Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.
Mallinckrodt CH; Bell J; Liu G; Ratitch B; O'Kelly M; Lipkovich I; Singh P; Xu L; Molenberghs G
Ther Innov Regul Sci; 2020 Mar; 54(2):353-364. PubMed ID: 32072593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
